As a newly discovered immune checkpoint molecule, T cell immunoglobulin mucin-3 (Tim-3) antibodies have curative effects in laboratory-scale studies in several tumors, and some of them have entered phase I/II clinical trials (Table 1); therefore, Tim-3 has the potential to become a new target for cancer immunotherapy. The gene discussed is HAVCR2; the disease is cancer.